Viravaxx is a drug development company dedicated to hepatitis B vaccine development with a lead vaccine candidate (VVX001) currently in phase II clinical trials:
• Interim data confirm that VVX001 induces a preS-specific IgG antibody response in vaccine naïve adults and in chronically infected patients.
• Abstracts presenting interim data were recently accepted for publication at the American Association for the Study of Liver Diseases (AASLD) and HepDART.
• Viravaxx works with a board of international renowned hepatologists including Anna Lok, Fabien Zoulim, Florian van Bömmel, Patrick Kennedy and Peter Ferenci.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Mariannengasse 14/9, Vienna,austria
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.viravaxx.com
- Keywords
- Vaccines, Hepatitis B, Drug Development.
- HQ
- Vienna
Viravaxx Ag Questions
Viravaxx Ag's website is http://www.viravaxx.com
Viravaxx Ag's LinkedIn profile is https://at.linkedin.com/company/viravaxx
Viravaxx Ag has
1 employees.
View email and phone details for 1
employees at Viravaxx Ag.
Viravaxx Ag's industry is
Biotechnology Research
Viravaxx Ag's top competitors are
Planqc,
Welser Profile,
Lyfjaver,
Tier Mobility,
Earlybird Venture Capital,
Contorion,
Celus,
Yokoy,
Adina Apartment Hotels.
Viravaxx Ag's categories are Biotechnology Research
Viravaxx Ag's founding year is 2017
